NASDAQ:KNSA - Kiniksa Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.83 +3.61 (+29.54 %) (As of 03/31/2020 12:30 PM ET) Add Compare Today's Range$14.40Now: $15.83▼$17.5050-Day Range$11.00MA: $16.48▼$19.7652-Week Range$5.01Now: $15.83▼$21.50Volume90,719 shsAverage Volume267,124 shsMarket Capitalization$879.20 millionP/E RatioN/ADividend YieldN/ABeta-1.33 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40 co-stimulatory receptor; and KPL-045, a monoclonal antibody inhibitor of the CD30 ligand co-stimulatory molecule. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KNSA Previous Symbol CUSIPN/A CIKN/A Webhttp://www.kiniksa.com/ Phone781-439-9100Debt Debt-to-Equity RatioN/A Current Ratio8.68 Quick Ratio8.68Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.10 per share Price / Book3.86Profitability EPS (Most Recent Fiscal Year)($2.99) Net Income$-161,870,000.00 Net MarginsN/A Return on Equity-61.14% Return on Assets-54.38%Miscellaneous Employees111 Outstanding Shares55,540,000Market Cap$879.20 million Next Earnings Date5/7/2020 (Estimated) OptionableNot Optionable Receive KNSA News and Ratings via Email Sign-up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:KNSA Rates by TradingView Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions How has Kiniksa Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Kiniksa Pharmaceuticals' stock was trading at $16.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KNSA stock has decreased by 2.7% and is now trading at $15.67. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Kiniksa Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kiniksa Pharmaceuticals. When is Kiniksa Pharmaceuticals' next earnings date? Kiniksa Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Kiniksa Pharmaceuticals. How were Kiniksa Pharmaceuticals' earnings last quarter? Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) released its earnings results on Wednesday, February, 26th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.04. View Kiniksa Pharmaceuticals' earnings history. What price target have analysts set for KNSA? 4 brokers have issued 12 month target prices for Kiniksa Pharmaceuticals' shares. Their forecasts range from $18.00 to $35.00. On average, they expect Kiniksa Pharmaceuticals' share price to reach $25.67 in the next year. This suggests a possible upside of 63.8% from the stock's current price. View analysts' price targets for Kiniksa Pharmaceuticals. What are Wall Street analysts saying about Kiniksa Pharmaceuticals stock? Here are some recent quotes from research analysts about Kiniksa Pharmaceuticals stock: 1. According to Zacks Investment Research, "Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts, United States. " (2/5/2020) 2. Wedbush analysts commented, "Our estimated market value of the firm is $1.75B, which includes the asset value for tagraxofusp and 15% discount rate and 2% terminal growth rate. The probability of success is 66% for tagraxofusp in indications beyond BPDCN and 45% for SL-701. Assuming roughly 50.1M shares outstanding at the end of 2Q20, this leads to a 12-month price target of approximately $35 per share." (8/14/2019) Has Kiniksa Pharmaceuticals been receiving favorable news coverage? Media stories about KNSA stock have trended very positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kiniksa Pharmaceuticals earned a coverage optimism score of 3.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutKiniksa Pharmaceuticals. Are investors shorting Kiniksa Pharmaceuticals? Kiniksa Pharmaceuticals saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 1,351,500 shares, an increase of 9.0% from the February 27th total of 1,240,000 shares. Based on an average daily trading volume, of 267,700 shares, the short-interest ratio is currently 5.0 days. Currently, 9.0% of the company's stock are short sold. View Kiniksa Pharmaceuticals' Current Options Chain. Who are some of Kiniksa Pharmaceuticals' key competitors? Some companies that are related to Kiniksa Pharmaceuticals include BridgeBio Pharma (BBIO), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), FibroGen (FGEN), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), PTC Therapeutics (PTCT), Emergent Biosolutions (EBS), GW Pharmaceuticals PLC- (GWPH), Genmab A/S (GMAB), Ultragenyx Pharmaceutical (RARE), PPD (SDGR) and Amicus Therapeutics (FOLD). What other stocks do shareholders of Kiniksa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Amarin (AMRN), Agile Therapeutics (AGRX), Clovis Oncology (CLVS), Crispr Therapeutics (CRSP), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Athenex (ATNX), Global Blood Therapeutics (GBT), Nabriva Therapeutics (NBRV) and Sangamo Therapeutics (SGMO). Who are Kiniksa Pharmaceuticals' key executives? Kiniksa Pharmaceuticals' management team includes the following people: Mr. Sanj K. Patel, CEO & Chairman (Age 49)Mr. Stephen Mahoney, Pres & COO (Age 47)Dr. John F. Paolini, Chief Medical Officer (Age 53)Mr. Chris Heberlig, Exec. VP & CFO (Age 43)Mark Ragosa C.F.A., VP of Investor Relations When did Kiniksa Pharmaceuticals IPO? (KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Kiniksa Pharmaceuticals' stock symbol? Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA." How do I buy shares of Kiniksa Pharmaceuticals? Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Kiniksa Pharmaceuticals' stock price today? One share of KNSA stock can currently be purchased for approximately $15.67. How big of a company is Kiniksa Pharmaceuticals? Kiniksa Pharmaceuticals has a market capitalization of $870.31 million. The company earns $-161,870,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Kiniksa Pharmaceuticals employs 111 workers across the globe. View additional information about Kiniksa Pharmaceuticals. What is Kiniksa Pharmaceuticals' official website? The official website for Kiniksa Pharmaceuticals is http://www.kiniksa.com/. How can I contact Kiniksa Pharmaceuticals? Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 781-439-9100 or via email at [email protected] MarketBeat Community Rating for Kiniksa Pharmaceuticals (NASDAQ KNSA)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 141 (Vote Outperform)Underperform Votes: 149 (Vote Underperform)Total Votes: 290MarketBeat's community ratings are surveys of what our community members think about Kiniksa Pharmaceuticals and other stocks. Vote "Outperform" if you believe KNSA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KNSA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/31/2020 by MarketBeat.com StaffFeatured Article: How accurate is the Rule of 72?
